Bayesian cell therapy process optimization

Evan Claes,Tommy Heck,Kathleen Coddens,Maarten Sonnaert,Jan Schrooten,Jan Verwaeren

DOI: https://doi.org/10.1002/bit.28669

IF: 3.8

2024-02-21

Biotechnology and Bioengineering

Abstract:Parallel noisy Bayesian optimization, an efficient iterative experimental design methodology, is evaluated on two in silico bioprocesses and one in vitro bioprocess. The method facilitated a reduction in experimental load of about 50%, compared to the industry state‐of‐the‐art. Optimizing complex bioprocesses poses a significant challenge in several fields, particularly in cell therapy manufacturing. The development of customized, closed, and automated processes is crucial for their industrial translation and for addressing large patient populations at a sustainable price. Limited understanding of the underlying biological mechanisms, coupled with highly resource‐intensive experimentation, are two contributing factors that make the development of these next‐generation processes challenging. Bayesian optimization (BO) is an iterative experimental design methodology that addresses these challenges, but has not been extensively tested in situations that require parallel experimentation with significant experimental variability. In this study, we present an evaluation of noisy, parallel BO for increasing noise levels and parallel batch sizes on two in silico bioprocesses, and compare it to the industry state‐of‐the‐art. As an in vitro showcase, we apply the method to the optimization of a monocyte purification unit operation. The in silico results show that BO significantly outperforms the state‐of‐the‐art, requiring approximately 50% fewer experiments on average. This study highlights the potential of noisy, parallel BO as valuable tool for cell therapy process development and optimization.

biotechnology & applied microbiology